Cancer Family
Glandular Cell Neoplasm
CI-CAN-00000188Explore in graph →
Non-malignant2,825 active trials43 approved drugs426 evidence items
- NCIt
- C7132
Loading cancer entity…
Cancer Family
CI-CAN-00000188Explore in graph →
Clinical trials
10,211 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06342401 | Early Onset Colorectal Cancer Detection(ENCODE) | recruiting | — | 400 | City of Hope Medical CenterOTHER | 4 | Jul 7, 2026 | clinicaltrials |
| NCT06342414 | An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer(ELUCIDATE) | recruiting | — | 400 | City of Hope Medical CenterOTHER | 2 | Jul 7, 2026 |
| clinicaltrials |
| NCT06342440 | Early Detection of Advanced Adenomas and Colorectal Cancer(AACRC) | recruiting | — | 2,000 | City of Hope Medical CenterOTHER | 5 | Jul 7, 2026 | clinicaltrials |
| NCT06824363 | ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu | recruiting | Early Phase 1 | 34 | University of California, IrvineOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06996249 | Prospective Data Collection Initiative on Thoracic Malignancies(DuTOC) | recruiting | — | 12,000 | Dutch Society of Physicians for Pulmonology and TuberculosisOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07011654 | Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) | recruiting | Phase 1 / Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07224750 | A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer(MiGIC) | recruiting | — | 1,000 | City of Hope Medical CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04389632 | A Study of Sigvotatug Vedotin in Advanced Solid Tumors | recruiting | Phase 1 | 1,006 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 7 | Jul 6, 2026 | clinicaltrials |
| NCT04634357 | ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma(ARYA-2) | recruiting | Phase 1 / Phase 2 | 12 | Eureka Therapeutics Inc.INDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06710756 | Lead-212 PSV359 Therapy for Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 112 | Perspective TherapeuticsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07042256 | Feasibility of MR-Informed Adaptive Marker-less SBRT in Patients With Bilateral Hip Prostheses Undergoing SBRT for Localized Prostate Cancer(HIP-PRO) | recruiting | N/A | 13 | University of ZurichOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07552168 | INSPIRE: INnovative SABR for Prostate Cancer All IREland | recruiting | Phase 2 | 136 | Cancer Trials IrelandNETWORK | 2 | Jul 6, 2026 | clinicaltrials |
| NCT07683845 | Patient-Derived Organoid-on-a-Chip Model for Personalized Prediction of Chemotherapy Efficacy in Pancreatic Cancer | recruiting | — | 164 | Beijing Daxiang Biotech Co., LtdINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05852041 | rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance | recruiting | Early Phase 1 | 40 | Northwestern UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06184152 | CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules | recruiting | N/A | 600 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06260943 | Targeted Navigation in Hepatocellular Carcinoma (HCC) | recruiting | N/A | 210 | University of MiamiOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06813898 | An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial | recruiting | Early Phase 1 | 27 | Northwestern UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07087158 | A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma | recruiting | Phase 2 | 30 | Imbioray (Hangzhou) Biomedicine Co., Ltd.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07436793 | Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial | recruiting | Phase 2 | 140 | New Mexico Cancer Research AllianceOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07647744 | To Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced/Metastatic Renal Cancer | recruiting | Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04472767 | Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | recruiting | Phase 2 | 35 | University of California, IrvineOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05530343 | Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance(SWAT-BE) | recruiting | N/A | 2,298 | University of Colorado, DenverOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07022015 | Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy(POPF) | recruiting | N/A | 100 | Minia UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07265271 | Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)(CENTINEL) | recruiting | — | 600 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07549399 | SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC(CRITⅡ) | recruiting | Phase 3 | 204 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07595874 | Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3(NEST3) | recruiting | Phase 2 | 100 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07679061 | First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE) | recruiting | — | 200 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06101290 | Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)(LAYOVER) | recruiting | N/A | 150 | University of California, DavisOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07316101 | Clinical Trial of an Anti-Fog Drainage Device for Endoscopic Endonasal Sellar Region Tumor Surgery | recruiting | N/A | 20 | West China HospitalOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07493447 | Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures | recruiting | Early Phase 1 | 30 | Eben RosenthalOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07675967 | Clonal Hematopoiesis Chemotherapy and Radiation Effects Study(CH CARE) | recruiting | — | 5,000 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05276791 | EMR Versus ESD for Barrett's Neoplasia(REMOVE-RCT) | recruiting | N/A | 331 | St. Antonius HospitalOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05377996 | A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors | recruiting | Phase 1 / Phase 2 | 360 | Day One Biopharmaceuticals, Inc.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05516628 | Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma(EMPHASIS) | recruiting | Phase 2 | 30 | National Cancer Centre, SingaporeOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05677802 | Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer | recruiting | N/A | 40 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06780787 | FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery | recruiting | Phase 2 | 26 | City of Hope Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07327489 | Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)(ELEPHAS-05) | recruiting | — | 2,000 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07458347 | A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation | recruiting | Phase 1 | 145 | Kestrel Therapeutics, Inc.OTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07587268 | Molecular Profiling for Risk Stratification in Appendiceal Cancer | recruiting | — | 400 | City of Hope Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673029 | A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer | recruiting | Phase 3 | 228 | GeneQuantum Healthcare (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06959641 | XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer | recruiting | Phase 2 | 33 | Jochen LorchOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07019844 | PSMA PET for the Staging and Management of Hepatocellular Carcinoma | recruiting | — | 90 | VA Office of Research and DevelopmentFED | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07042919 | Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer | recruiting | Phase 1 / Phase 2 | 59 | Devalingam MahalingamOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07321197 | Radical Nephrectomy With vs Without Template Lymph Node Dissection in High-Risk Renal Cell Carcinoma (T-LND RCC)(RECLND) | recruiting | N/A | 220 | Tianjin Medical University Second HospitalOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07385703 | Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. | recruiting | Phase 3 | 752 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.INDUSTRY | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07669220 | A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial)(STAR) | recruiting | Phase 2 | 76 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05770531 | Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy | recruiting | Phase 2 | 160 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06835972 | A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) | recruiting | Phase 1 / Phase 2 | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07660627 | Determining Minimal Residual Disease Using ctDNA Deep Sequencing(CIT-SEQ) | recruiting | N/A | 34 | Masaryk Memorial Cancer InstituteOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04114136 | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | recruiting | Phase 2 | 72 | Dan ZandbergOTHER | 1 | Jun 23, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 7, 2026source: clinicaltrials